Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Sathianathen, Niranjan; Dahm, Philipp; Brown, Sarah Jane; Oestreich, Makinna; Gupta, Shilpa; Konety, Badrinath R.; Kunath, Frank

doi:10.1002/14651858.cd013245

Cited by 5 publications

(39 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these 5 SRs, 3 were published in 2020, 13,16,17 1 in 2019, 14 and 1 in 2018. 15 The literature searches ranged from database inception to May 15, 2020.…”

Section: Methodsmentioning

confidence: 99%

“…Two SRs contained NMAs 15,17 and 3 contained meta-analyses (MAs). 13,14,16 One was a Cochrane review. 16 There was overlap of included primary studies across the SRs.…”

Section: Methodsmentioning

confidence: 99%

“…13,14,16 One was a Cochrane review. 16 There was overlap of included primary studies across the SRs. The extent of this overlap is summarized in Appendix 5.…”

Section: Methodsmentioning

confidence: 99%

“…The primary author for 3 of the SRs were from China. 13,15,17 One SR was authored by an investigator in the US 16 and 1 from France. 14 Two primary studies were authored by investigators in Japan 18,19 and 1 by an investigator in Canada.…”

Section: Country Of Originmentioning

confidence: 99%

“…One study 17 limited study inclusion to those with patients18 years and older, another limited to patients older than 70 years, 14 and 3 studies had no age restrictions. 13,[15][16][17] The number of mCSPC patients included in each SR ranged from 499 to 11,494.…”

Section: Patient Populationmentioning

confidence: 99%

See 4 more Smart Citations

Abiraterone Acetate for Metastatic Castration-Sensitive Prostate Cancer

Shane¹,

Walter²

2021

cjht

View full text Add to dashboard Cite

The use of abiraterone acetate for the treatment of metastatic castration-sensitive prostate cancer is clinically effective. Compared with standard of care, abiraterone acetate was associated with increased overall survival, increased prostate cancer–specific survival, increased progression-free survival, and improved quality of life. Patients treated with abiraterone acetate were at higher risk for grade III to grade V adverse events (severe, life-threatening, or fatal) and were more likely to discontinue treatment compared with standard of care. The incremental cost-effectiveness ratios for both brand and generic abiraterone acetate were estimated to be higher than common willingness-to-pay thresholds.

show abstract

“…Of these 5 SRs, 3 were published in 2020, 13,16,17 1 in 2019, 14 and 1 in 2018. 15 The literature searches ranged from database inception to May 15, 2020.…”

Section: Methodsmentioning

confidence: 99%

“…Two SRs contained NMAs 15,17 and 3 contained meta-analyses (MAs). 13,14,16 One was a Cochrane review. 16 There was overlap of included primary studies across the SRs.…”

Section: Methodsmentioning

confidence: 99%

“…13,14,16 One was a Cochrane review. 16 There was overlap of included primary studies across the SRs. The extent of this overlap is summarized in Appendix 5.…”

Section: Methodsmentioning

confidence: 99%

Section: Country Of Originmentioning

confidence: 99%

Section: Patient Populationmentioning

confidence: 99%

See 3 more Smart Citations

Abiraterone Acetate for Metastatic Castration-Sensitive Prostate Cancer

Shane¹,

Walter²

2021

cjht

View full text Add to dashboard Cite

show abstract

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Sathianathen

Oestreich

Brown

et al. 2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Androgen‐targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer

et al. 2022

View full text Add to dashboard Cite

Background Prostate cancer and multiple neurodegenerative diseases (NDD) share an age‐associated pattern of onset. Therapy of prostate cancer is known to impact cognitive function. The objective of this study was to determine the impact of multiple classes of androgen‐targeting therapeutics (ATT) on the risk of NDD. Methods A retrospective cohort study of men aged 45 and older with prostate within the US‐based Mariner claims data set between January 1 and 27, 2021. A propensity score approach was used to minimize measured and unmeasured selection bias. Disease risk was determined using Kaplan–Meier survival analyses. Results Of the 1,798,648 men with prostate cancer, 209,722 met inclusion criteria. Mean (SD) follow‐up was 6.4 (1.8) years. In the propensity score‐matched population, exposure to ATT was associated with a minimal increase in NDD incidence (relative risk [RR], 1.07; 95% CI, 1.05–1.10; p < 0.001). However, GnRH agonists alone were associated with significantly increased NDD risk (RR, 1.47; 95% CI, 1.30–1.66; p <0.001). Abiraterone, commonly administered with GnRH agonists and low‐dose prednisone, was associated with a significantly decreased risk (RR, 0.77; 95% CI, 0.68–0.87; p < 0.001) of any NDD. Conclusions Among patients with prostate cancer, GnRH agonist exposure was associated with an increased NDD risk. Abiraterone acetate reduced the risks of Alzheimer's disease and Parkinson's disease conferred by GnRH agonists, whereas the risk for ALS was reduced by androgen receptor inhibitors. Outcomes of these analyses contribute to addressing controversies in the field and indicate that GnRH agonism may be a predictable instigator of risk for NDD with opportunities for risk mitigation in combination with another ATT.

show abstract

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Cited by 5 publications

References 36 publications

Abiraterone Acetate for Metastatic Castration-Sensitive Prostate Cancer

Abiraterone Acetate for Metastatic Castration-Sensitive Prostate Cancer

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Androgen‐targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer

Contact Info

Product

Resources

About